Filing Flows › Artivion (AORT) › Q2 2026 › vs Q1 2026
Artivion (AORT) Q2 2026 vs Q1 2026 (quarter over quarter)
Artivion's revenue rose $9.4M (+8%) from $116M in Q1 2026 to $126M in Q2 2026. The biggest changes: Products +$8.5M (+9%); Preservation services +$957K (+4%).
Artivion, Q2 2026: revenue $126M (+11% year over year), operating margin -6.7%, net loss $13.5M, operating cash flow −$1.3M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Aortic stent grafts | $46.4M | $44.4M | $2.0M | +5% |
| On-X | $30.5M | $26.0M | $4.6M | +18% |
| Surgical sealants | $19.3M | $18.8M | $482K | +3% |
| Other | $3.7M | $2.3M | $1.4M | +62% |
| Products | $99.9M | $91.4M | $8.5M | +9% |
| Preservation services | $25.9M | $24.9M | $957K | +4% |
| Revenue | $126M | $116M | $9.4M | +8% |
| Net loss | $13.5M | −$1.4M | $14.9M | — |
| Costs & expenses | $139M | $117M | $21.9M | +19% |
| Operating costs | $134M | $111M | $23.6M | +21% |
| Interest & other, net | $3.3M | $5.4M | −$2.1M | -39% |
| Income tax | $1.8M | −$1.1M | $2.9M | — |
| Cost of revenue | $45.2M | $40.9M | $4.4M | +11% |
| Research & development | $9.1M | $8.8M | $214K | +2% |
| SG&A | $79.8M | $60.8M | $19.0M | +31% |
| Operating cash sources | $16.2M | $13.6M | $2.6M | +19% |
| Depreciation & amortization | $6.7M | $6.3M | $408K | +6% |
| Share-based compensation | $8.2M | $8.4M | −$250K | -3% |
| Cash used in operations | $1.3M | −$1.2M | $2.4M | — |
| Net loss absorbed | $13.5M | −$1.4M | $14.9M | — |
| Working capital & other | $2.7M | $15.0M | −$12.3M | -82% |
Questions
How much did Artivion's revenue grow quarter over quarter in Q2 2026?
Artivion's revenue rose $9.4M (+8%) from $116M in Q1 2026 to $126M in Q2 2026.
What drove Artivion's revenue change in Q2 2026?
Products +$8.5M (+9%); Preservation services +$957K (+4%).